Drug Development · global
Efficacy Falls Short: argenx to Terminate Phase 3 Trial of efgartigimod in Sjögren’s Disease
The UNITY trial, designed to determine whether treatment could reduce systemic disease activity, is to be stopped following an interim analysis. No new safety signals were identified, but full data are still needed to clarify why this treatment approach fell short.
For patients with moderate to severe Sjögren’s disease, treatment expectations extend beyond relieving dryness to controlling disease activity throughout the body. Those hopes have now encountered a setback: on October 8, argenx announced that it would terminate the Phase 3 UNITY trial evaluating subcutaneous efgartigimod after an independent data monitoring committee determined, following an interim analysis, that the study would not meet its primary endpoint.
Both the announcement on argenx’s website and the release issued through GlobeNewswire stated that the committee recommended stopping the study based on an assessment of futility; RTTNews also reported the decision. The company said the trial’s safety profile was consistent with existing efgartigimod data, with no new safety signals identified. The decision to stop the trial was therefore based on its efficacy prospects, but this does not mean that complete safety results have been released.
UNITY used a randomized, double-blind, placebo-controlled design, enrolling adults receiving stable standard therapy who were positive for anti-Ro/SSA autoantibodies and had a clinical disease activity index, clinESSDAI, of at least 6. Participants were assigned in a one-to-one ratio to receive weekly subcutaneous efgartigimod or placebo. The primary endpoint was the change from baseline in clinESSDAI at week 48, a measure of systemic disease activity.
This design addressed the burden of Sjögren’s disease beyond dry eyes and dry mouth. Sjögren’s disease is a chronic autoimmune disease that may also involve fatigue, joint pain, and manifestations outside the glands. Efgartigimod binds to the neonatal Fc receptor (FcRn), reducing circulating IgG autoantibodies. UNITY sought to determine whether this effect could translate into improvements in patients’ systemic disease activity.
The announcements have not provided the actual difference between the two groups on the primary endpoint, statistical values, or detailed subgroup results, so the extent and reasons for the insufficient efficacy cannot yet be determined. The interim futility determination supports stopping this study, but it is insufficient to conclude that all patients had no response, and it cannot be directly extrapolated to other indications or all FcRn therapies.
argenx said it would conduct a comprehensive analysis after the study ends and the database is locked. In addition to the primary endpoint, UNITY also planned to assess the proportion of patients with low disease activity, overall treatment response, and patient-reported symptoms. Whether these data can explain the setback remains to be seen when the full results become available. What can be confirmed now is that this Phase 3 trial can no longer follow its originally planned course to provide the primary efficacy evidence supporting efgartigimod as a treatment for moderate to severe Sjögren’s disease.